NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free CAPR Stock Alerts $5.42 +0.05 (+0.93%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$5.33▼$5.4950-Day Range$4.20▼$7.1052-Week Range$2.68▼$8.22Volume111,219 shsAverage Volume296,766 shsMarket Capitalization$170.75 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Capricor Therapeutics alerts: Email Address Capricor Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside342.8% Upside$24.00 Price TargetShort InterestBearish11.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to $0.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.80 out of 5 starsMedical Sector817th out of 915 stocksPharmaceutical Preparations Industry392nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Capricor Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.40% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 2.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CAPR. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 5 news articles for Capricor Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows5 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($0.83) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Capricor Therapeutics Stock (NASDAQ:CAPR)Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More CAPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CAPR Stock News HeadlinesMay 9, 2024 | globenewswire.comCapricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingMay 8, 2024 | globenewswire.comCapricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 6, 2024 | globenewswire.comCapricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13April 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical AdvancementsApril 26, 2024 | uk.investing.comCapricor aligns with FDA on drug pathway for muscular dystrophyApril 25, 2024 | markets.businessinsider.comOptimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial PositionApril 24, 2024 | markets.businessinsider.comCapricor Announces Positive Type-B Interaction With FDA For CAP-1002 In Treating DMDMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…April 24, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn SituationApril 24, 2024 | globenewswire.comCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyApril 19, 2024 | markets.businessinsider.comNurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative MedicineApril 10, 2024 | finance.yahoo.comWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should KnowApril 3, 2024 | investing.comCapricor Therapeutics Inc (CAPR)March 21, 2024 | globenewswire.comCapricor Therapeutics to Present at Upcoming Investor ConferencesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial ProspectsMarch 14, 2024 | finance.yahoo.comEarnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech LandscapeMarch 6, 2024 | markets.businessinsider.comCapricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical ProgressMarch 6, 2024 | globenewswire.comCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 3, 2024 | finance.yahoo.comCapricor Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 3, 2024 | seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comQ4 2023 Capricor Therapeutics Inc Earnings CallFebruary 29, 2024 | benzinga.comRecap: Capricor Therapeutics Q4 EarningsFebruary 29, 2024 | finance.yahoo.comCapricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD TherapyFebruary 29, 2024 | globenewswire.comCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/09/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$40.00 Low Stock Price Target$8.00 Potential Upside/Downside+342.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-88.52% Pretax Margin-88.52% Return on Equity-299.67% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual Sales$25.18 million Price / Sales6.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book7.42Miscellaneous Outstanding Shares31,503,000Free Float27,723,000Market Cap$170.75 million OptionableOptionable Beta4.06 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More ExecutivesKey CompetitorsGreenwich LifeSciencesNASDAQ:GLSISeres TherapeuticsNASDAQ:MCRBscPharmaceuticalsNASDAQ:SCPHGossamer BioNASDAQ:GOSSInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 5,827 shares on 5/1/2024Ownership: 0.018%David B MusketBought 410 shares on 10/12/2023Total: $1,127.50 ($2.75/share)David B MusketBought 5,083 shares on 10/9/2023Total: $14,334.06 ($2.82/share)Paul Gisbert AuwaerterBought 5,000 shares on 10/6/2023Total: $14,200.00 ($2.84/share)David B MusketBought 2,500 shares on 10/4/2023Total: $7,250.00 ($2.90/share)View All Insider TransactionsView All Institutional Transactions CAPR Stock Analysis - Frequently Asked Questions Should I buy or sell Capricor Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CAPR shares. View CAPR analyst ratings or view top-rated stocks. What is Capricor Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 1 year target prices for Capricor Therapeutics' shares. Their CAPR share price targets range from $8.00 to $40.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 342.8% from the stock's current price. View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts. How have CAPR shares performed in 2024? Capricor Therapeutics' stock was trading at $4.89 at the beginning of 2024. Since then, CAPR shares have increased by 10.8% and is now trading at $5.42. View the best growth stocks for 2024 here. When is Capricor Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our CAPR earnings forecast. How can I listen to Capricor Therapeutics' earnings call? Capricor Therapeutics will be holding an earnings conference call on Monday, May 13th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) announced its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.21. The biotechnology company had revenue of $12.09 million for the quarter, compared to analyst estimates of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative trailing twelve-month return on equity of 299.67%. What ETF holds Capricor Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 2,030 shares of CAPR stock, representing 0.30% of its portfolio. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD). Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BNP Paribas Financial Markets (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CAPR) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetryTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.